Switch theme
Sign up to access all valuation multiples
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.
1984
1.4K+
LTM Revenue $145M
LTM EBITDA $61.3M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Concord Biotech has a last 12-month revenue (LTM) of $145M and a last 12-month EBITDA of $61.3M.
In the most recent fiscal year, Concord Biotech achieved revenue of $141M and an EBITDA of $64.3M.
Concord Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Concord Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $145M | XXX | $141M | XXX | XXX | XXX |
| Gross Profit | $108M | XXX | $105M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $61.3M | XXX | $64.3M | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 46% | XXX | XXX | XXX |
| EBIT | $57.3M | XXX | $52.9M | XXX | XXX | XXX |
| EBIT Margin | 39% | XXX | 38% | XXX | XXX | XXX |
| Net Profit | $45.0M | XXX | $43.5M | XXX | XXX | XXX |
| Net Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Concord Biotech's stock price is INR 1747 (or $20).
Concord Biotech has current market cap of INR 183B (or $2.1B), and EV of INR 179B (or $2.1B).
See Concord Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.1B | XXX | XXX | XXX | XXX | $0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Concord Biotech has market cap of $2.1B and EV of $2.1B.
Concord Biotech's trades at 15.6x EV/Revenue multiple, and 33.9x EV/EBITDA.
Equity research analysts estimate Concord Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Concord Biotech has a P/E ratio of 47.5x.
See valuation multiples for Concord Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 14.5x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBITDA | 34.2x | XXX | 33.9x | XXX | XXX | XXX |
| EV/EBIT | 36.6x | XXX | 41.1x | XXX | XXX | XXX |
| EV/Gross Profit | 19.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 47.5x | XXX | 51.4x | XXX | XXX | XXX |
| EV/FCF | 140.3x | XXX | 123.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialConcord Biotech's last 12 month revenue growth is 20%
Concord Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $38K for the same period.
Concord Biotech's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Concord Biotech's rule of X is 91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Concord Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 91% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Concord Biotech acquired XXX companies to date.
Last acquisition by Concord Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Concord Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Concord Biotech founded? | Concord Biotech was founded in 1984. |
| Where is Concord Biotech headquartered? | Concord Biotech is headquartered in India. |
| How many employees does Concord Biotech have? | As of today, Concord Biotech has 1.4K+ employees. |
| Who is the CEO of Concord Biotech? | Concord Biotech's CEO is Mr. Ankur Vaid. |
| Is Concord Biotech publicy listed? | Yes, Concord Biotech is a public company listed on BOM. |
| What is the stock symbol of Concord Biotech? | Concord Biotech trades under 543960 ticker. |
| When did Concord Biotech go public? | Concord Biotech went public in 2023. |
| Who are competitors of Concord Biotech? | Similar companies to Concord Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Concord Biotech? | Concord Biotech's current market cap is $2.1B |
| What is the current revenue of Concord Biotech? | Concord Biotech's last 12 months revenue is $145M. |
| What is the current revenue growth of Concord Biotech? | Concord Biotech revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Concord Biotech? | Current revenue multiple of Concord Biotech is 14.5x. |
| Is Concord Biotech profitable? | Yes, Concord Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Concord Biotech? | Concord Biotech's last 12 months EBITDA is $61.3M. |
| What is Concord Biotech's EBITDA margin? | Concord Biotech's last 12 months EBITDA margin is 42%. |
| What is the current EV/EBITDA multiple of Concord Biotech? | Current EBITDA multiple of Concord Biotech is 34.2x. |
| What is the current FCF of Concord Biotech? | Concord Biotech's last 12 months FCF is $15.0M. |
| What is Concord Biotech's FCF margin? | Concord Biotech's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Concord Biotech? | Current FCF multiple of Concord Biotech is 140.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
